We focus on the Tumor Microenvironment (TME)
OncoResponse is leveraging our proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancer and extending cures to the greatest number of patients who otherwise would not respond to immunotherapy.
Adaptive immune systems of Elite Cancer Responders are the key
Our technology works by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). These Elite Cancer Responders harbor antibodies that modulate immune cells in the tumor microenvironment which has enabled OncoResponse to discover and develop a pipeline of therapies for cancer as single agents or in combination with other immunotherapy.
We have a strong partnership with MD Anderson Cancer Center
MD Anderson Cancer Center (MDACC) is one of the world's largest cancer centers and a leader in immunotherapy research, clinical development and patient care. We formed a broad strategic alliance with MDACC and they made an equity investment in OncoResponse.
Our experience and support is deep
We are guided by accomplished leaders who have a successful track record of drug discovery, development and FDA approvals. OncoResponse has an experienced board of directors, an expert scientific and clinical advisory panel and strong venture and strategic investors.